Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients
暂无分享,去创建一个
K. Leroy | F. Goldwasser | N. Dupin | M. Avril | S. Aractingi | A. Jouinot | B. Blanchet | P. Boudou-Rouquette | J. Alexandre | O. Huillard | N. Kramkimel | N. Franck | J. Arrondeau | J. Chanal | V. Heidelberger
[1] Tore Wentzel-Larsen,et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. , 2016, Clinical nutrition.
[2] A. Weaver,et al. Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer. , 2016, Gynecologic oncology.
[3] Haa-Na Song,et al. Prognostic impact of sarcopenia in patients with diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone , 2016, Journal of cachexia, sarcopenia and muscle.
[4] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[5] T. Pawlik,et al. Role of frailty and sarcopenia in predicting outcomes among patients undergoing gastrointestinal surgery. , 2016, World journal of gastrointestinal surgery.
[6] M. Sawyer,et al. Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens , 2016, Cancer medicine.
[7] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[8] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[9] J. Larkin,et al. The cost of ipilimumab toxicity: a single-centre analysis , 2015, Melanoma research.
[10] G. Linette,et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[11] S. Parsons,et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] J. W. Kim,et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy , 2015, Supportive Care in Cancer.
[13] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[14] Julien Taieb,et al. Sarcopenia Is Linked to Treatment Toxicity in Patients With Metastatic Colorectal Cancer , 2014, Nutrition and cancer.
[15] L. Mccargar,et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] V. Baracos,et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. , 2013, The Journal of clinical endocrinology and metabolism.
[17] O. Mir,et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients , 2013, British Journal of Cancer.
[18] O. Mir,et al. Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma , 2012, PloS one.
[19] Michael J. Englesbe,et al. Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma , 2011, Annals of Surgical Oncology.
[20] L. Birdsell,et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Tony Reiman,et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.
[22] Tony Reiman,et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.
[23] S. Steinberg,et al. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.
[24] Tony Reiman,et al. Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity , 2007, Clinical Cancer Research.